Johan Richter

Johan Richter

Lunds Universitet

H-index: 47

Europe-Sweden

About Johan Richter

Johan Richter, With an exceptional h-index of 47 and a recent h-index of 29 (since 2020), a distinguished researcher at Lunds Universitet, specializes in the field of gene therapy, chronic myeloid leukemia.

His recent articles reflect a diverse array of research interests and contributions to the field:

Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide …

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI

Successful tyrosine kinase inhibitor discontinuation outside clinical trials—data from the population‐based Swedish chronic myeloid leukaemia registry

Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal

Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Johan Richter Information

University

Position

Molecular Medicine and Gene Therapy Sweden

Citations(all)

9148

Citations(since 2020)

4504

Cited By

6785

hIndex(all)

47

hIndex(since 2020)

29

i10Index(all)

109

i10Index(since 2020)

66

Email

University Profile Page

Lunds Universitet

Google Scholar

View Google Scholar Profile

Johan Richter Skills & Research Interests

gene therapy

chronic myeloid leukemia

Top articles of Johan Richter

Title

Journal

Author(s)

Publication Date

Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects

Annals of Hematology

Inge GP Geelen

Stein-Erik Gullaksen

Mette M Ilander

Ulla Olssen-Strömberg

Satu Mustjoki

...

2023/6

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

The Journal of clinical investigation

Jani Huuhtanen

Mette Ilander

Bhagwan Yadav

Olli MJ Dufva

Hanna Lähteenmäki

...

2022/9/1

Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide …

American Journal of Hematology

Torsten Dahlén

Gustaf Edgren

Per Ljungman

Hjalmar Flygt

Johan Richter

...

2022/4

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI

Leukemia

Johan Richter

Anna Lübking

Stina Söderlund

Kourosh Lotfi

Berit Markevärn

...

2021/8

Successful tyrosine kinase inhibitor discontinuation outside clinical trials—data from the population‐based Swedish chronic myeloid leukaemia registry

British journal of haematology

Hjalmar Flygt

Fredrik Sandin

Torsten Dahlén

Arta Dremaine

Anna Lübking

...

2021/6

Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal

Ilana Moscatelli

Elena Almarza

Axel Schambach

David Ricks

Ansgar Schulz

...

2021/3/12

Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study

European journal of haematology

Hjalmar Flygt

Stina Söderlund

Jesper Stentoft

Johan Richter

Perttu Koskenvesa

...

2021/12

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Andreas Hochhaus

Michele Baccarani

Richard T Silver

C Schiffer

Jane F Apperley

...

2020/4

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

Leukemia Research

Stina Söderlund

Inger Persson

Mette Ilander

Joëlle Guilhot

Henrik Hjorth-Hansen

...

2020/3/1

Increased Risk of Chronic Myeloid Leukemia Following Gastric Conditions Indicating Helicobacter pylori Infection: A Case–Control Study

Cancer Epidemiology, Biomarkers & Prevention

Gunnar Larfors

Johan Richter

Anders Själander

Leif Stenke

Martin Höglund

2020/1/1

Generation of gene-corrected functional osteoclasts from osteopetrotic induced pluripotent stem cells

Stem cell research & therapy

Xiaojie Xian

Roksana Moraghebi

Henrik Löfvall

Anders Fasth

Kim Henriksen

...

2020/12

A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells

haematologica

Sofia von Palffy

Niklas Landberg

Carl Sandén

Dimitra Zacharaki

Mansi Shah

...

2020/8

See List of Professors in Johan Richter University(Lunds Universitet)

Co-Authors

H-index: 83
Stefan Karlsson

Stefan Karlsson

Lunds Universitet

H-index: 70
Kimmo Porkka

Kimmo Porkka

Helsingin yliopisto

H-index: 64
Bjorn T. Gjertsen

Bjorn T. Gjertsen

Universitetet i Bergen

H-index: 62
Satu Mustjoki

Satu Mustjoki

Helsingin yliopisto

H-index: 50
Hans Ehrencrona

Hans Ehrencrona

Lunds Universitet

H-index: 49
martin hoglund

martin hoglund

Uppsala Universitet

academic-engine